↓ Skip to main content

Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice

Overview of attention for article published in Molecular Neurodegeneration, June 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter
3 X users

Citations

dimensions_citation
76 Dimensions

Readers on

mendeley
68 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice
Published in
Molecular Neurodegeneration, June 2013
DOI 10.1186/1750-1326-8-18
Pubmed ID
Authors

Katherine D LaClair, Kebreten F Manaye, Dexter L Lee, Joanne S Allard, Alena V Savonenko, Juan C Troncoso, Philip C Wong

Abstract

Though the precise cause(s) of Alzheimer's disease (AD) remain unknown, there is strong evidence that decreased clearance of β-amyloid (Aβ) from the brain can contribute to the disease. Therapeutic strategies to promote natural Aβ clearance mechanisms, such as the protein apolipoprotein-E (APOE), hold promise for the treatment of AD. The amount of APOE in the brain is regulated by nuclear receptors including retinoid X receptors (RXRs). Drugs that activate RXRs, including bexarotene, can increase APOE and ABCA1 production, and have been shown to decrease the Aβ burden and improve cognition in mouse models of Aβ amyloidosis. Although recent bexarotene studies failed to replicate the rapid clearance of Aβ from brains, behavioral and cognitive effects of this compound remain controversial.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 3%
Netherlands 1 1%
Unknown 65 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 14 21%
Researcher 14 21%
Student > Bachelor 8 12%
Student > Doctoral Student 6 9%
Professor 4 6%
Other 9 13%
Unknown 13 19%
Readers by discipline Count As %
Neuroscience 17 25%
Biochemistry, Genetics and Molecular Biology 10 15%
Agricultural and Biological Sciences 10 15%
Pharmacology, Toxicology and Pharmaceutical Science 7 10%
Medicine and Dentistry 4 6%
Other 3 4%
Unknown 17 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 August 2013.
All research outputs
#13,386,010
of 22,712,476 outputs
Outputs from Molecular Neurodegeneration
#655
of 844 outputs
Outputs of similar age
#103,824
of 196,875 outputs
Outputs of similar age from Molecular Neurodegeneration
#3
of 9 outputs
Altmetric has tracked 22,712,476 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 844 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.1. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 196,875 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.